Nusinersen in infantile-onset spinal muscular atrophy: benefits, high cost

  • PDF / 167,031 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 93 Downloads / 218 Views

DOWNLOAD

REPORT

1173-5503/20/0864-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 17 Oct 2020 No. 864

1

Data Loading...

Recommend Documents
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

144 15 1MB

Spinal Muscular Atrophy

163 112 3MB

Proximal Spinal Muscular Atrophy

171 12 6MB

Spinal Muscular Atrophy

168 71 35MB

Spinal Muscular Atrophy/Lambert Eaton Myasthenic Syndrome

159 57 6MB

Choosing Life with Spinal Muscular Atrophy Type 1

153 88 236KB

Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy

156 99 363KB

High-throughput screening reveals novel mutations in spinal muscular atrophy patients

159 24 501KB

Brain MRI abnormalities in a child with spinal muscular atrophy type II

156 106 488KB

Scoliosis in spinal muscular atrophy: is the preoperative magnetic resonance imaging necessary?

162 70 493KB

Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy

157 75 2MB

Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing

168 95 257KB